North America Vital in the Non-Melanoma Skin Cancer Treatment
Market
In a new report titled ‘Non-Melanoma Skin Cancer Treatment Market: Global
Industry Analysis 2012 – 2016 and Forecast 2017 – 2025,’ Persistence Market
Research analyzes the global non-melanoma skin cancer treatment market over an
eight year forecast period 2017 – 2025 and throws light on the various factors
impacting revenue growth of the market over the said period. The report highlights
the market forecasts for the different segments and presents deeper insights for
informed decision making.
Region – High Prevalence of Non-Melanoma Skin Cancer in North America
North America is estimated to hold a market share of roughly 55% in the global nonmelanoma skin cancer treatment market in 2017 and is anticipated to have the highest
attractiveness index of 3.0 during the forecast period. Non-melanoma skin cancer is
more prevalent in senior citizens and the Population Reference Bureau estimates that
Americans over the age of 65 will double to almost 100 million by 2060.
Request to view table of content @
https://www.persistencemarketresearch.com/market-research/non-melanoma-skincancer-market/toc
Treatment Type – Radiation Therapy Larger than Chemotherapy and Photodynamic
Therapy
Radiation therapy is larger than chemotherapy and photodynamic therapy combined,
making it imperative for key stakeholders in the non-melanoma skin cancer treatment
market to focus on this treatment type. Radiation therapy is poised to be worth more
than US$ 4.7 Bn by end 2025. Within radiation therapy, companies may wish to
target superficial radiation therapy.
Indication – Basal Cell Carcinoma Dominates the Non-Melanoma Skin Cancer
Treatment Market
Even though squamous cell carcinoma is predicted to record a higher CAGR of 6.4%
from 2017-2025, it is unlikely to outpace basal cell carcinoma anytime soon as the
latter is likely to value at approx. thrice the size of the former by end 2025. The
attractiveness index of basal cell carcinoma is 1.5, considerably larger than the 0.5 of
squamous cell carcinoma during the same period.
A sample of this report is available upon request @
https://www.persistencemarketresearch.com/samples/3648
End User – Hospitals Popular Channel in the Non-Melanoma Skin Cancer Treatment
Market
The treatment modalities for non-melanoma skin cancer usually require expensive
radiation therapy. Therefore, hospitals are preferred over ambulatory surgical centers
and specialty clinics in the non-melanoma skin cancer treatment market. The hospital
segment is expected to reach a value of US$ 2 Bn in 2017 itself.
Competition Dashboard in the Non-Melanoma Skin Cancer Treatment Market
Persistence Market Research has profiled some of the largest companies actively
involved in the non-melanoma skin cancer treatment market. These include Almirall
S.A., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and
Company, Elekta AB, F. Hoffmann-La Roche Ltd., Merck & Co., Novartis AG,
Mylan NV, Sun Pharmaceutical Industries, Varian Medical Systems, and Sensus
Healthcare.
Non-melanoma skin cancer places a high economic burden on countries with minimal
medical treatment options, particularly at the metastatic stage. Many pharmaceutical
companies are now trying to develop treatment options for late-stage non-melanoma
skin cancer. In addition, companies seek to use their existing drugs to effectively
tackle squamous cell and basal cell carcinoma. Major players such as Bristol-Myers
Squibb, Genentech, and Merck are working on gaining approval for their drugs to
treat non-melanoma skin cancer.
Regulatory authorities and governmental bodies worldwide are adopting a number of
cost-containment measures in the developed world. They are shifting from a volume
to value-based system and this is driven by steps taken by life sciences companies
and governments. The measures include profit and risk sharing, outcome-based
pricing, competitive tendering, and price control. The value-based healthcare system
strives to achieve maximum value for every dollar spent on healthcare and improve
outcomes by way of integrated care pathways. The system simultaneously levies
pricing pressure on medtech and biopharmaceutical companies and could potentially
impact R&D investment in crucial, lifesaving medical treatment technologies in the
long run.
Browse Complete Report @ https://www.persistencemarketresearch.com/marketresearch/non-melanoma-skin-cancer-market.asp
About Us:
Persistence Market Research (PMR) is a third-platform research firm. Our research
model is a unique collaboration of data analytics and market research methodology to
help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a
multi-disciplinary approach. At PMR, we unite various data streams from multidimensional sources. By deploying real-time data collection, big data, and customer
experience analytics, we deliver business intelligence for organizations of all sizes.
Our offerings include pre-built reports that address every major sale, customized
solutions to cater to client-specific needs, and consulting services to offer more value
addition. Our next-generation research approach for exploring emerging technologies
has allowed us to solve the most complex problems of clients. We do not follow a
reactive approach, but a pro-active one. Expert analysts at PMR keep a tab on nextgeneration technologies in their R&D phase and provide the latest insights into these
technologies when they are being commercialized. Our ground-breaking approach
allows us to deliver market solutions before the technologies reach the market.
Our client success stories feature a range of clients from Fortune 500 companies to
fast-growing startups. PMR’s collaborative environment is committed to building
industry-specific solutions by transforming data from multiple streams into a strategic
asset.
Contact Us:
Persistence Market Research
305 Broadway,7th Floor
New York City, NY 10007
United States
Tel: +1-646-568-7751
Email: [email protected]
Website: http://www.persistencemarketresearch.com/
[email protected]